An Analysis of Efficacy of Maintenance Dasatinib for Ph+ALL Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Phase II trial

Not Applicable

Recruiting

• Conditions: Ph+ Acute Lymphoblastic Leukemia

• Registration Number: JPRN-UMIN000025028
• Lead Sponsor: Kant Study Group for Cell Therapy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-28
• Study Completion: 2021-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Not provided

Exclusion Criteria

1.Ph+ALL patients with T315I 2.Patients who have increased or added immunosuppressants because of exacerbation of GVHD within 2 weeks before initiation of dasatinib administration 3.Patients who are negative for pretransplantation MRD and remain negative even after transplantation 4.Patients in whom infiltration of leukemia cells into the central nervous system cannot be controlled 5.Patients with poorly-controlled diabetes mellitus in spite of continuous use of insulin 6.Patients with poorly-controlled hypertension in spite of the use of antihypertensive drugs 7.Patients with uncontrollable infection 8.Patients with sinusoidal obstruction syndrome (SOS) 9.Patients with uncontrollable thrombotic microangiopathy (TMA) 10.Patients with active double cancer 11.Patients with psychiatric symptoms 12.Other patients who are deemed to be ineligible by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified